Leerink Partners analyst Marc Goodman maintained a Buy rating on Oculis Holding (OCS – Research Report) on March 13 and set a price target of $22.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Marc Goodman has given his Buy rating due to a combination of factors including the promising progress of Oculis Holding’s pipeline programs. The company has successfully aligned with the FDA to advance a precision medicine approach for licaminlimab (OCS-02) in treating dry eye disease. Furthermore, Oculis is preparing for further FDA discussions in the second half of 2025 regarding privosegtor (OCS-05) and its development program for acute optic neuritis, following positive proof-of-concept data reported earlier this year.
Additionally, the company’s lead program, OCS-01, is making significant strides with the DIAMOND program in diabetic macular edema expected to complete enrollment this year, with top-line data anticipated in early 2026. The NDA submission for post-ocular surgery remains on schedule for the first quarter of 2025. Oculis is considered a strong contender in the ophthalmology field, with three programs showing robust proof-of-concept data and moving towards registrational studies, which supports the Outperform rating and a price target of $22.
In another report released on March 13, H.C. Wainwright also reiterated a Buy rating on the stock with a $29.00 price target.